Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) - Total Assets
Latest total assets as of September 2025: $237.63 Million USD
Based on the latest financial reports, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) holds total assets worth $237.63 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Drugs Made In America Acquisition Corp. Ordinary Shares - Total Assets Trend (2024–2024)
This chart illustrates how Drugs Made In America Acquisition Corp. Ordinary Shares’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Drugs Made In America Acquisition Corp. Ordinary Shares - Asset Composition Analysis
Current Asset Composition (December 2024)
Drugs Made In America Acquisition Corp. Ordinary Shares's total assets of $237.63 Million consist of 906.1% current assets and -806.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 245.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2024)
This chart illustrates how Drugs Made In America Acquisition Corp. Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Drugs Made In America Acquisition Corp. Ordinary Shares Competitors by Total Assets
Key competitors of Drugs Made In America Acquisition Corp. Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
464680
KQ:464680
|
Korea | ₩31.23 Billion |
|
Cartesian Growth Corporation III Unit
NASDAQ:CGCTU
|
USA | $281.56 Million |
|
Azure Holding Group Corp
PINK:AZRH
|
USA | $16.92 Million |
|
Constellation Capital Corp.
V:CNST-P
|
Canada | CA$627.53K |
|
Little Fish Acquisition I Corp.
V:LILL-P
|
Canada | CA$56.48K |
|
Hana 30 Special Purpose Acquisition Company
KQ:469880
|
Korea | ₩17.89 Billion |
|
Chicane Capital I Corp.
V:CCIC-P
|
Canada | CA$199.07K |
|
Cuspis Capital II Ltd
V:CCII-P
|
Canada | CA$1.51 Million |
Drugs Made In America Acquisition Corp. Ordinary Shares - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Drugs Made In America Acquisition Corp. Ordinary Shares generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Drugs Made In America Acquisition Corp. Ordinary Shares is currently not profitable relative to its asset base.
Drugs Made In America Acquisition Corp. Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.06 | 0.00 | 0.37 |
| Quick Ratio | 0.06 | 0.00 | 0.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-428.42K | $ -588.90K | $ -132.89 |
Drugs Made In America Acquisition Corp. Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between Drugs Made In America Acquisition Corp. Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 517314.73 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | $550.82 |
| Market Capitalization | $284.95 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Drugs Made In America Acquisition Corp. Ordinary Shares's assets at a significant premium ( 517314.73x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Drugs Made In America Acquisition Corp. Ordinary Shares's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2024)
The table below shows the annual total assets of Drugs Made In America Acquisition Corp. Ordinary Shares from 2024 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $550.82 | -- |